The changing role of the endocrinologist in the care of patients with diabetic retinopathy
- 3 January 2014
- journal article
- review article
- Published by Springer Nature in Endocrine
- Vol. 46 (2) , 199-208
Abstract
Diabetic retinopathy (DR) is the most common microvascular complication of diabetes and still represents a leading cause of visual impairment in working age in industrialized countries. It develops following non proliferative (mild, moderate, or severe) and proliferative stages, the earliest being often asymptomatic and with diabetic macular edema potentially developing at any of these. The prevalence and incidence of DR increase with diabetes duration and worsening of metabolic and blood pressure control. Current approaches to prevent and/or treat DR include optimized control of blood glucose and blood pressure and screening for early identification of high risk, though still asymptomatic retinal lesions. Results from the recent clinical trials suggest a role for blockers of the renin–angiotensin system (angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers) and for fenofibrate in reducing progression and/or inducing regression of mild to moderate non proliferative DR. Intra-vitreal administration of anti-vascular endothelial growth factor agents was shown to reduce visual loss in more advanced stages of DR, especially in macular edema.Keywords
This publication has 88 references indexed in Scilit:
- Expanded 2-Year Follow-up of Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular EdemaOphthalmology, 2011
- Effects of Medical Therapies on Retinopathy Progression in Type 2 DiabetesNew England Journal of Medicine, 2010
- Modern-Day Clinical Course of Type 1 Diabetes Mellitus After 30 Years' DurationArchives of internal medicine (1960), 2009
- Renal and Retinal Effects of Enalapril and Losartan in Type 1 DiabetesNew England Journal of Medicine, 2009
- ADOLESCENTS WITH TYPE 2 DIABETESRetina, 2009
- Three-Year Follow-up of a Randomized Trial Comparing Focal/Grid Photocoagulation and Intravitreal Triamcinolone for Diabetic Macular EdemaArchives of Ophthalmology (1950), 2009
- The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIIOphthalmology, 2008
- Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trialThe Lancet, 2008
- Effects of Intensive Glucose Lowering in Type 2 DiabetesNew England Journal of Medicine, 2008
- A multifocal electroretinogram model predicting the development of diabetic retinopathyProgress in Retinal and Eye Research, 2006